15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
(18)F-AmBF3-MJ9: a novel radiofluorinated bombesin derivative for prostate cancer imaging.
Bc Cancer Agency
Studies toward the development of new silicon-containing building blocks for the direct (18)F-labeling of peptides.
Institute of Technology (Eth) Zurich
Heterobivalent dual-target probe for targeting GRP and Y1 receptors on tumor cells.
The Ohio State University
Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate.
Universit£
PD 176252--the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist.
Cambridge University Forvie Site
PD 165929 the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist
TBA
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity
TBA
Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.
Merck Research Laboratories
Discovery of substituted biphenyl imidazoles as potent, bioavailable bombesin receptor subtype-3 agonists.
Merck Research Laboratories
Structural assessment and biological evaluation of two N3S bombesin derivatives.
Institutes of Radioisotopes-Radiodiagnostic Products and Biology
Discovery of small molecule agonists for the bombesin receptor subtype 3 (BRS-3) based on an omeprazole lead.
Glaxosmithkline
Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.
National Center For Scientific Research Demokritos
Design of selective peptidomimetic agonists for the human orphan receptor BRS-3.
Technische UniversitäT MüNchen
